000170169 001__ 170169
000170169 005__ 20240229133707.0
000170169 0247_ $$2doi$$a10.1007/s00066-021-01827-9
000170169 0247_ $$2pmid$$apmid:34351449
000170169 0247_ $$2ISSN$$a0179-7158
000170169 0247_ $$2ISSN$$a1439-099X
000170169 0247_ $$2altmetric$$aaltmetric:111242445
000170169 037__ $$aDKFZ-2021-01793
000170169 041__ $$aEnglish
000170169 082__ $$a610
000170169 1001_ $$00000-0002-1445-1940$$aLiermann, Jakob$$b0
000170169 245__ $$aCarbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer.
000170169 260__ $$aHeidelberg$$bSpringer Medizin$$c2022
000170169 3367_ $$2DRIVER$$aarticle
000170169 3367_ $$2DataCite$$aOutput Types/Journal article
000170169 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1648719772_24556
000170169 3367_ $$2BibTeX$$aARTICLE
000170169 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000170169 3367_ $$00$$2EndNote$$aJournal Article
000170169 500__ $$a2022 Apr;198(4):378-387
000170169 520__ $$aData on management of locally recurrent pancreatic cancer (LRPC) after primary resection are limited. Recently, surprisingly high overall survival rates were reported after irradiation with carbon ions. Here, we report on our clinical experience using carbon ion radiotherapy as definitive treatment in LRPC at the Heidelberg Ion-Beam Therapy Center (HIT).Between 2015 and 2019, we treated 13 patients with LRPC with carbon ions with a median total dose of 48 Gy (RBE) in 12 fractions using an active raster-scanning technique at a rotating gantry. No concomitant chemotherapy was administered. Overall survival, local control, and toxicity rates were evaluated 18 months after the last patient finished radiotherapy.With a median follow-up time of 9.5 months, one patient is still alive (8%). Median OS was 12.7 months. Ten patients (77%) developed distant metastases. Additionally, one local recurrence (8%) and two regional tumor recurrences (15%) were observed. The estimated 1‑year local control and locoregional control rates were 87.5% and 75%, respectively. During radiotherapy, we registered one gastrointestinal bleeding CTCAE grade III (8%) due to gastritis. The bleeding was sufficiently managed with conservative therapy. No further higher-grade acute or late toxicities were observed.We demonstrate high local control rates in a rare cohort of LRPC patients treated with carbon ion radiotherapy. The observed median overall survival rate was not improved compared to historical in-house data using photon radiotherapy. This is likely due to a high rate of distant tumor progression, highlighting the necessity of additional chemotherapy.
000170169 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000170169 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000170169 650_7 $$2Other$$aCarbon ion radiotherapy
000170169 650_7 $$2Other$$aLocally recurrent pancreatic cancer
000170169 650_7 $$2Other$$aPancreatic cancer
000170169 650_7 $$2Other$$aParticle therapy
000170169 650_7 $$2Other$$aRadiation oncology
000170169 7001_ $$aBen-Josef, Edgar$$b1
000170169 7001_ $$aSyed, Mustafa$$b2
000170169 7001_ $$0P:(DE-HGF)0$$aDebus, Juergen$$b3
000170169 7001_ $$0P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aHerfarth, Klaus$$b4
000170169 7001_ $$aNaumann, Patrick$$b5
000170169 773__ $$0PERI:(DE-600)2003907-4$$a10.1007/s00066-021-01827-9$$n4$$p378-387$$tStrahlentherapie und Onkologie$$v198$$x1439-099X$$y2022
000170169 909CO $$ooai:inrepo02.dkfz.de:170169$$pVDB
000170169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000170169 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000170169 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000170169 9141_ $$y2021
000170169 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-26$$wger
000170169 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000170169 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-26
000170169 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000170169 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSTRAHLENTHER ONKOL : 2021$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-11
000170169 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-11
000170169 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000170169 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000170169 980__ $$ajournal
000170169 980__ $$aVDB
000170169 980__ $$aI:(DE-He78)E050-20160331
000170169 980__ $$aI:(DE-He78)HD01-20160331
000170169 980__ $$aUNRESTRICTED